Long-acting amylin receptor agonists and uses thereof
AssigneeEli Lilly and Company
InventorsMilata Mary Abraham, Daniel Anthony Briere, Lili Guo, Samantha Grace Lyons Keyser, John Lee, Hongchang Qu
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity and/or chronic weight management, dyslipidemia and/or NASH. The disclosure relates to compounds that agonize the amylin receptor and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity, and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.
Claims18
A compound comprising a sequence selected from the group consisting of SEQ ID NO:
- 22, SEQ ID NO:23, SEQ ID NO:24, and SEQ ID NO:25, or a pharmaceutically acceptable salt thereof.
A method of treating a condition in a patient in need thereof, comprising administering to the patient an effective amount of a compound comprising a sequence selected from the group consisting of SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, and SEQ ID NO:25, or a pharmaceutically acceptable salt thereof, wherein the condition is selected from the group consisting of diabetes, obesity, NASH, and dyslipidemia.
A method of lowering food intake, body weight, blood glucose, or triglycerides, in a patient in need thereof, comprising administering to the patient an effective amount of a compound comprising a sequence selected from the group consisting of SEQ ID NO:22, SEQ ID NO:
- 23, SEQ ID NO:24, and SEQ ID NO:25, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.